Ionis Pharmaceuticals IONS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborative Agreement Revenue | $541.42M+64.9% | $465.79M+40.0% | $510.28M+23.0% | $523.73M+26.4% | $328.33M-9.7% | |
| Commercial | $467.49M+51.0% | $435.85M+48.7% | $380.24M+32.9% | $340.37M+15.6% | $309.65M+3.1% | |
| Other Commercial | $35.82M+14.5% | $35M-2.1% | $35.8M— | $36.62M— | $31.28M— | |
| Other Royalties | $21.28M+18.3% | $24.16M+15.0% | $22.12M-13.1% | $19.87M-32.3% | $17.99M-47.3% | |
| Research And Development Revenue | $590.7M+44.9% | $507.86M+23.2% | $586.72M+13.5% | $603.68M+16.3% | $407.6M-14.4% | |
| Royalty | $279.69M+2.8% | $285.53M+11.0% | $287.08M+15.6% | $278.2M+11.4% | $272.09M+7.1% | |
| Spinraza Royalties | $207.98M-7.8% | $212.28M-1.8% | $221.93M+3.6% | $223.24M-0.5% | $225.65M-1.3% | |
| Wainua Joint Development Revenue | $49.29M-37.8% | $42.08M-47.0% | $76.44M-25.0% | $79.95M-23.7% | $79.27M-29.6% | |
| Wainus Royalties | $50.43M+77.2% | $49.09M+143% | $43.04M+319% | $35.09M+615% | $28.45M+2,429% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ionis Pharmaceuticals break its business down?
- Ionis Pharmaceuticals (IONS) reports revenue by product across 11 parts — Collaborative Agreement Revenue, Commercial, DAWNZERA Sales, Other Commercial and Other Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Ionis Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ionis Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
